Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90 — HSP-HEMATO  

Acute B Lymphoblastic Leukemia (B-ALL) Clinical Trial

Official title: Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90

Status Recruiting

Clinical Trial Summary

NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Acute B Lymphoblastic Leukemia (B-ALL)
• Acute T Lymphoblastic Leukemia (T-ALL)
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

• NCT number: NCT04437420
• Study type: Observational
• Source: Centre Hospitalier Universitaire Dijon
• Contact: François GIRODON
• Phone: 0380295710
• Email: francois.girodon@chu-dijon.fr
• Status: Recruiting
• Start date: November 1, 2019
• Completion date: September 2021